ECOG 5204 (CINJ 070601): Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation.

Trial Profile

ECOG 5204 (CINJ 070601): Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Rectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2013 Planned end date changed from 1 Feb 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 22 Jan 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Jan 2013 Planned end date changed from 1 May 2020 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top